26 Nov 2024
TAVI for pure aortic regurgitation with a dedicated CE-mark device: an underdiagnosed and undertreated disease
Sponsored by JenaValve Technology
Anchorperson:
A. Baumbach
Summary
Explore this session to learn about the unmet needs in aortic regurgitation (AR) and the performance of dedicated TAVI devices for AR. Discover why new thresholds for severe AR are necessary, and how traditional methods may underestimate its severity. Gain insights into the TRILOGY THV system, the first dedicated TAVR option for high-risk symptomatic patients with severe AR. Finally, understand the future of TAVI for AR, including the need for further data and improved clinical pathways to address remaining patient needs.
Learning Objectives
- To learn how to improve the treatment of aortic regurgitation, a disease that is underdiagnosed and undertreated
- To learn about TAVI for aortic regurgitation
- To explore the future of TAVI for aortic regurgitation
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide004.jpg)
/slide005.jpg)
/slide006.jpg)
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide004.jpg)
/slide005.jpg)
/slide006.jpg)
/slide007.jpg)
/slide008.jpg)
/slide009.jpg)
/slide010.jpg)
/slide011.jpg)
/slide012.jpg)
/slide013.jpg)
/slide014.jpg)
/slide015.jpg)
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide004.jpg)
/slide005.jpg)
/slide006.jpg)
/slide007.jpg)
/slide008.jpg)
/slide009.jpg)
/slide010.jpg)
/slide011.jpg)
/slide012.jpg)
/slide013.jpg)
/slide014.jpg)
/slide015.jpg)
/slide016.jpg)
/slide017.jpg)
/slide018.jpg)
/slide019.jpg)
/slide020.jpg)
/slide021.jpg)
/slide022.jpg)
/slide023.jpg)
/slide024.jpg)
/slide025.jpg)
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide004.jpg)
/slide005.jpg)
/slide006.jpg)
/slide007.jpg)
/slide008.jpg)
/slide009.jpg)
/slide010.jpg)
/slide011.jpg)